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ABSTRACT
To explore the key genes associated with both PCOS and breast cancer, we 
overlapped the synchronously differently expressed genes in two obese insulin-
resistant GEO datasets in muscle tissue and genes exert essential roles in breast cancer 
prognosis together base on the following reasons: (1) Androgens excess is believed to 
contribute to the onset of both PCOS and breast cancer. (2) PCOS is usually complicated 
with metabolic symptoms, such as obesity and insulin-resistance. (3) Muscle is the main 
place where energy metabolism and material metabolism take place. Consequently, 
53 genes were found, functionally enriched in pathways such as pyruvate metabolism, 
muscle system process and development of primary male sexual characteristics etc. We 
further lay our eyes on genes correlated with male sexual characteristics, which may 
be involved in the onset of both PCOS and breast cancer. Three genes were indicated 
to be associated with this process, including hydroxysteroid (17-beta) dehydrogenase 
4/HSD17B4, platelet-derived growth factor receptor, alpha polypeptide/PDGFRA and 
high-mobility group box 2/HMGB2. Gene-drug interaction network about the three 
genes were then constructed. Drugs or chemicals that contribute to correcting the 
disorder of lipid metabolism were detected to restore the abnormal expression of the 
three genes in PCOS, such as simvastatin, bezafibrate, fenofibrate et al, which provide 
further choices for managing patients with PCOS.
INTRODUCTION
Polycystic ovary syndrome, which is short for 
PCOS, is a highly complex endocrine and metabolic 
disorder, characterized by clinical and/or biological signs 
of androgen excess with prolonged menstrual cycle, 
oligo ovulation or anovulation, hirsutism, polycystic 
ovarian, and high level of circulating androgens, and 
is frequently associated with insulin resistance and 
obesity. Hyperandrogenism and/or hyperandrogenemia 
are suggested to contribute to the pathogenesis of PCOS 
[1, 2]. Nevertheless, the insight mechanism is still largely 
unknown.
The pathogenesis of breast cancer, is initiated 
by excessive androgen and estrogen. Large amount of 
data has proved that high serum level of androgens and 
estrogens were positively correlated with increased risk 
of breast cancer incidences and breast cancer recurrences 
[3–13]. Since androgen excess could contribute to the 
pathogenesis of both PCOS and breast cancer, there might 
be an overlap between dysregulated genes in PCOS and 
genes associated with breast cancer.
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In this study, we first choose the commonly different 
expressed genes in two GEO datasets of obese insulin-
resistant PCOS women in muscle tissue and then overlap 
them with genes that has prognostic value in breast cancer. 
Then, function enrichment analysis was performed on 
these overlapped genes. Gene correlated with androgen 
metabolism and male sexual characteristics were selected 
for further analysis. Finally, gene-drug interaction network 
between selected genes and drugs or chemicals that could 
result in their decreased or increased expression was 
constructed. 
RESULTS
Potent key genes in pathogenesis of PCOS
It is well known that PCOS and breast cancer are 
both correlated with disorder of sex hormone metabolism, 
and they are both metabolic disease. Since high level of 
androgens and estrogens have been proved to positively 
correlated with increased risk of breast cancer, we sought 
to overlap dysregulated genes in PCOS with prognostic 
genes in breast cancer to find common therapeutic targets 
of PCOS and breast cancer. The schematic structure of the 
article was shown in Figure 1.
Two publicly available datasets of gene expression 
profile in skeletal muscle of insulin-resistant obese PCOS 
women and their age- and body mass index matched 
corresponding healthy controls were downloaded and 
analyzed to explore the commonly different-expressed 
genes in both GSE datasets. Both datasets were completed 
at the platform of Affymetrix Human Genome U133 Plus 
2.0 Array.
Disorder of sex hormone metabolism contribute to 
onset of both PCOS and breast cancer. Besides, PCOS 
is suggested to be the risk factor for breast cancer [14]. 
Thus, we further performed the Kaplan-Meier analysis 
in 3554 breast cancer patients in different stages using 
the differently expressed genes in both GEO datasets. 
Those genes differently expressed in both datasets 
and have influence on breast cancer prognosis were 
hypothesized to be the key genes in pathogenesis of 
PCOS (Supplementary Table 1). Of the 60 probe sets, 53 
genes were discovered. 
Gene ontology analysis of potential key genes in 
PCOS
Gene ontology analysis of the 53 potent key 
genes in pathogenesis of PCOS was carried out. To 
our interest, several well-known processes involved in 
PCOS were discovered in our top-ranked gene ontology 
processes, such as pyruvate metabolic process, and 
development of primary male sexual characteristics etc. 
(Table 1).
Genes suggested in development of primary male 
sexual characteristics
PCOS, characterized by elevated male sex hormone 
levels, is one of most common endocrine disorder in 
women of reproductive age. Of the 53 potent key genes 
in pathogenesis of PCOS, HMGB2, PDGFRA and 
HSD17B4 were demonstrated in the development of 
male sexual characteristics or male sex differentiation. 
HMGB2 and HSD17B4 were down-regulated in obese 
PCOS women, while PDGFRA was up-regulated in obese 
PCOS women (Figure 2A, 2B). In terms of prognosis of 
breast cancer, high expression of HMGB2 and PDGFRA 
in breast cancer indicated poor prognosis, while high 
expression of HSD17B in breast cancer suggested the 
opposite effect (Figure 3). The above results indicated 
that reduced expression of HSD17B4 and increased 
expression of PDGFRA in PCOS may be a risk factor of 
PCOS developing into breast cancer. While the decreased 
expression of HMGB2 may be the compensatory response 
the body correspond to PCOS.
Construction of network between chemicals and 
genes involved in development of male sexual 
characteristics
Next, we sought to explore how HMGB2, PDGFRA 
and HSD17B4 and available chemicals or drugs could 
influence each other. Gene-drug interaction network 
was constructed based on data from The Comparative 
Toxicogenomics Database (CTD) (Figure 4). This 
network demonstrated that several drugs and sex 
hormones could influence the expression of HMGB2, 
PDGFRA and HSD17B4. Green circles represent genes 
down-regulated in PCOS, while red circles indicate 
genes up-regulated in PCOS. For instance, several lipid-
lowering drug elevated the expression of HSD17B4, 
which down-regulated in PCOS and down-expression of 
which indicate poor prognosis in breast cancer. Secondly, 
another lipid-lowering drug simvastatin suppressed the 
expression of PDGFRA, which up-regulated in PCOS and 
over-expression of which also suggest poor prognosis. 
Furthermore, pirinixic acid, an agonist of PPARa that 
controls the expression of genes involved in fatty acid 
utilization, restore the decreased expression of HSD17B4 
and HMGB2 in PCOS. In addition, folic Acid, choline, and 
sex hormone (estrogen, testosterone and progesterone) and 
its derivatives (ethinyl estradiol) and analogs (coumestrol, 
diethylstilbestrol and pregnenolone carbonitrile) were 
also indicated in this network, as you can see in Figure 4. 
Androgen excess coupled with estrogen excess are well-
known to contribute to pathogenesis of PCOS. Here, we 
discovered from the gene-drug interaction network that 
testosterone resulted in decreased expression of HMGB2, 
while estradiol and progesterone gave rise to up-regulation 
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of PDGFRA, which is in accordance with the expression 
of HMGB2 and PDGFRA in PCOS.
DISCUSSION
PCOS, as a complex endocrine and metabolic 
disorder, the underlying molecular mechanisms remains 
largely unknown. Numerous studies point towards adipose 
tissue and insulin resistance as the key elements in the 
development of the disorder, particularly in young patients 
with increased LH and hyperandrogenism (a consequence 
of hyperinsulinemia) [15–17], while other researchers 
would suggest an over-active GnRH pulse generator as 
the primary abnormality [18]. 
Our study report here is the first to overlap genes 
differently expressed in muscle tissue of obese insulin-
resistant PCOS women and genes exert their roles in 
breast cancer prognosis to find the common key genes and 
potential therapeutic targets of PCOS and breast cancer.
Skeletal muscle accounts for the majority of glucose 
metabolism suggesting an important role in metabolic 
disorder. In this study, we compare gene expression of 
muscle tissue in obese insulin-resistant PCOS women and 
their age- and body mass index- matched healthy control 
women in two GSE datasets. The synchronously expressed 
genes in both datasets were then used to perform prognosis 
analysis in breast cancer patients. Fifty-three genes were 
found, which we hypothesized to be the potent key genes 
contribute to the onset of PCOS.
Excess androgens and estrogens are believed to 
contribute to the pathogenesis of PCOS, although the 
specific mechanism is still unclear [2]. According to our 
results, HMGB2, PDGFRA and HSD17B4 which involved 
in development of primary male sexual characteristics 
are 3 of the 53 potent key genes in pathogenesis of 
PCOS. HSD17B is a group of ethanol dehydrogenase, 
which controls the last step in formation of androgens. 
HSD17B4 involves in the degradation of androstenediol to 
testosterone [19, 20], down expression of which in PCOS 
may result in the accumulation of androstenediol in blood 
circulation, which may be partly responsible for androgen 
excess induced PCOS phenotype. We also discovered that 
PDGFRA, a cell surface tyrosine kinase receptor involved 
in mesenchymal cell proliferation and male-specific 
mesonephric cell migration [21], is found up-regulated 
in obese PCOS women, which may contribute to the 
hyperandrogenism and appearance male characters.
Dysregulation of fatty acid metabolism is a 
typical manifestation of PCOS syndrome, and targeting 
dyslipidemia appear to have a more beneficial effect [22]. 
We demonstrated that through gene-drug interaction 
network many available drugs that suggested to restore 
the dysregulation of lipid metabolism are efficient in 
correcting the abnormal gene expression of HMGB2, 
PDGFRA and HSD17B4 in PCOS. Thus, our results 
suggested the indicative value of HMGB2, PDGFRA 
and HSD17B4 to be the important genes in pathogenesis 
of PCOS on one hand, and on another hand, the 
hypolipidemia drug detected from our network could 
provide more choices for treatment of disorders of lipid 
metabolism in obese PCOS women.
The molecular mechanism of polycystic ovarian 
syndrome, which is short for PCOS, is still unclear at 
present, due to heterogeneity and confounding factors. 
Figure 1: Flow chart of this study. First, two PCOS datasets were selected from Gene Expression Omnibus for screening common 
genes associated with PCOS. Then, the prognostic value of these genes were evaluated using our merged breast cancer dataset which 
containing 3554 samples. Next, function enrichment analysis of selected genes were performed. In the end, gene-drug interaction network 
was constructed and drugs that could potentially influencing the three genes were indicated.
Oncotarget69523www.impactjournals.com/oncotarget
Here we first combined the differentially expressed 
genes in PCOS and genes that have prognostic value of 
breast cancer together to explore common key genes in 
pathogenesis of PCOS and breast cancer, considering the 
similar pathogenesis of hyperandrogenism in both PCOS 
and breast cancer. The strategy of taking the differential 
expressed genes in PCOS and the genes of prognostic 
value of a certain disease that related to PCOS together 
may provide a new way to screen key genes associated 
with the onset of a PCOS in the future. In addition, these 
key genes would be potential therapeutic targets for both 
PCOS and breast cancer.
MATERIALS AND METHODS
Ethics statement
We are entitled to freely use the Gene Expression 
Omnibus (GEO) datasets in National Center for 
Biotechnology Information databases by meeting with 
Table 1: Gene ontology analysis of 53 key genes
GO Terms Genes p-Value 
pyruvate metabolic process SLC16A3, LDHB, SLC16A7 7.10E-03
muscle system process CALD1, RYR3, MYH4, MSTN 1.40E-02
development of primary male sexual 
characteristics HMGB2, PDGFRA, HSD17B4 1.70E-02
male sex differentiation HMGB2, PDGFRA, HSD17B4 2.10E-02
response to activity MYH4, MSTN 3.60E-02
organic acid catabolic process ALDH6A1, AASS, HSD17B4 4.40E-02
protein import into nucleus, docking IPO4, TNPO2 5.00E-02
nucleobase metabolic process ALDH6A1, AMPD3 6.70E-02
organic acid transport SLC16A3, SLC16A7, SLC38A1 7.40E-02
sex differentiation HMGB2, PDGFRA, HSD17B4 7.70E-02
Figure 3: Kaplan-Meier plot of the relapse free survival of 3554 breast cancer patients based on HMGB2, PDGFRA 
and HSD17B4, respectively. (p value was calculated by Logrank test, significance was defined as p < 0.05).
Figure 2: Genes involved in development of primary male sex characteristics. The expression of HMGB2, PDGFRA and 
HSD17B4 in insulin-resistant obese PCOS women and their age- and body mass index- matched controls in two different GEO datasets 
were demonstrated. (p values were calculated by unpaired two-tailed t-test, error bars represent mean ± SEM).
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its freedom-to-publish criteria. The Research Ethics 
Committee in Peking University Third Hospital waived 
the requirement for ethical approval of this study because 
the registry is a de-identified database.
Selection of differently expressed genes in PCOS
Two publicly available datasets were downloaded 
to identify the differently expressed genes in polycystic 
ovarian syndrome. The cDNA microarray of GSE8157 and 
GSE6798 were all performed using the HG-U133 Plus 2.0 
expression array from Affymetrix. Each dataset contains 
more than 10 samples in both PCOS patients group and 
healthy control group respectively. 
GSE8157 contains expression data from skeletal 
muscle of 10 obese women with PCOS metabolically 
characterized by a euglycemic-hyperinsulinemic clamp, 
and 13 obese healthy control women. GSE6798 contains 
expression data of skeletal muscle from 16 obese women 
with PCOS and 13 age- and body mass index- matched 
obese healthy control women, metabolically characterized 
by euglycemic-hyperinsulinemic clamp and indirect 
calorimetry. Criteria in both datasets included irregular 
periods with cycle length > 35 days during last year, 
elevated free testosterone levels ( > 0.035 nmol/l), and/
or hirsutism (total Ferriman-Gallwey score > 7), and the 
absence of diabetes, hypertension, hyperprolactinemia, 
hypothyroidism, and adrenal enzyme defects. Healthy 
control volunteers had regular menses, normal glucose 
tolerance, and no family history of diabetes. In GSE8157, 
all PCOS patients accepted to withdraw oral contraceptives 
for more than 3 months before using barrier contraception 
combined with spermatocidal cream during the study 
period. In GSE 6798, no subjects were taking medicines 
known to affect hormonal or metabolic parameters. 
Differently expressed genes in GSE8157 were 
selected using the criteria of fold change more than 1.5 
both up-regulated and down-regulated with p-value less 
Figure 4: The gene-drug interaction network. The network shows us how available drugs or chemicals could decrease or increase 
the expression of HMGB2, PDGFRA and HSD17B4. For example, simvastatin could decrease the expression of PDGFRA, while estradiol 
could increase the expression of PDGFRA.
Oncotarget69525www.impactjournals.com/oncotarget
than 0.05, and further verified by synchronously expressed 
in GSE 6798 with p-value of less than 0.05.
Identification of hub genes in pathogenesis of 
PCOS by survival analysis
The differently expressed genes of PCOS using 
both GSE 8157 and GSE6798 were further conducted for 
Kaplan-Meier analysis of relapse-free survival (RFS). Our 
merged dataset containing 3554 breast cancer patients in 
different stages were included for relapse-free survival 
analysis. Specific methods for building this dataset was 
described previously [23]. Hazard ratio is to weigh the 
relative influence of genes on prognosis. Genes with 
hazard ratio of more than 1 was deemed as potential 
oncogene, high expression of which correlated with bad 
prognosis of breast cancer. While genes with hazard 
ratio of less than 1 was considered as potential tumor 
suppressor gene, high expression of which correlated 
with good prognosis. Genes differently expressed in both 
GSE 8157 and GSE6798 and of prognostic value of breast 
cancer progression were deemed as hub genes which may 
play an important role in pathogenesis of PCOS.
Generation of genes-drug interaction network
The Comparative Toxicogenomics Database 
(CTD) [24] was conducted to explore the genes-drug 
interaction network. To be specific, genes was searched 
in the CTD database for drugs or chemicals that could 
result in their decreased or increased expression. Then 
sex hormone related chemicals and lipid-lowering drugs 
were selected based on their relationship with polycystic 
ovarian syndrome.
Statistical analysis
Clinical prognosis of breast cancer and gene 
expression profiling were analyzed using standard 
statistical tests including the Logrank test and unpaired 
t-test respectively. Differently expressed genes with 
p-value of less than 0.05 was considered as of significance. 
Hazard ratio of either more than 1 or less than 1 with 
p-value of less than 0.05 was deemed as of prognostic 
value in breast cancer progression.
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